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Key messages
What is the key question?
 ► What risk stratification tool should you use in com-
munity-acquired pneumonia?
What is the bottom line?
 ► Pneumonia-specific tools provide better discrimina-
tion of patients at high risk of adverse outcome than 
generic sepsis tools.
Why read on?
 ► This paper assesses commonly used risk strat-
ification tools in a pragmatic patient population 
comparing newer tools such as quick Sequential 
(Sepsis-related) Organ Failure Assessment tool with 
established scores.
AbstrAct
background Community-acquired pneumonia (CAP) is a 
leading cause of sepsis worldwide. Prompt identification 
of those at high risk of adverse outcomes improves 
survival by enabling early escalation of care. There are 
multiple severity assessment tools recommended for 
risk stratification; however, there is no consensus as to 
which tool should be used for those with CAP. We sought 
to assess whether pneumonia-specific, generic sepsis or 
early warning scores were most accurate at predicting 
adverse outcomes.
Methods We performed a retrospective analysis of all 
cases of CAP admitted to a large, adult tertiary hospital in 
the UK between October 2014 and January 2016. All cases 
of CAP were eligible for inclusion and were reviewed by a 
senior respiratory physician to confirm the diagnosis. The 
association between the CURB65, Lac-CURB-65, quick 
Sequential (Sepsis-related) Organ Failure Assessment tool 
(qSOFA) score and National Early Warning Score (NEWS) 
at the time of admission and outcome measures including 
intensive care admission, length of hospital stay, in-
hospital, 30-day, 90-day and 365-day all-cause mortality 
was assessed.
results 1545 cases were included with 30-day mortality 
of 19%. Increasing score was significantly associated with 
increased risk of poor outcomes for all four tools. Overall 
accuracy assessed by receiver operating characteristic 
curve analysis was significantly greater for the CURB65 
and Lac-CURB-65 scores than qSOFA. At admission, a 
CURB65 ≥2, Lac-CURB-65 ≥moderate, qSOFA ≥2 and 
NEWS ≥medium identified 85.0%, 96.4%, 40.3% and 
79.0% of those who died within 30 days, respectively. 
A Lac-CURB-65 ≥moderate had the highest negative 
predictive value: 95.6%.
conclusion All four scoring systems can stratify 
according to increasing risk in CAP; however, when a 
confident diagnosis of pneumonia can be made, these data 
support the use of pneumonia-specific tools rather than 
generic sepsis or early warning scores.
IntroductIon
Community-acquired pneumonia (CAP) is 
the fourth leading cause of death worldwide 
when combined with lower respiratory tract 
infections.1 It is associated with significant 
mortality2 and frequently leads to sepsis3 4 
with mortality rates rising to 30%.5 Early iden-
tification of patients with severe CAP enables 
modification of management strategies and 
improves outcomes for patients.6–8
To identify those at risk of poor outcomes, 
guidelines for management of CAP and sepsis 
suggest risk stratification tools should be 
used9–11; however there is no consensus as to 
which tool should be used.11–16
Severity assessment tools have been devel-
oped specifically for identifying patients at 
risk of deterioration due to sepsis. The quick 
Sequential (Sepsis-related) Organ Failure 
Assessment tool (qSOFA)15 is the recom-
mended tool to screen patients with suspected 
infection outside the intensive care unit 
(ICU)11 17–19 (one point for each of altered 
mentation, respiratory rate (RR) ≥22 and 
systolic blood pressure (SBP) ≤100 mm Hg, 
with a score ≥2 suggesting high risk for dete-
rioration).15 More generic tools designed to 
predict deterioration regardless of aetiology 
have also been designed, such as the National 
Early Warning Score (NEWS), widely used 
in the English National Health Service.16 
NEWS is a composite score assessing level of 
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alertness, RR, blood pressure (BP), heart rate, oxygen 
saturation and temperature with increasing values for 
more abnormal measurements (see online supplemen-
tary eTable 1 for a full description). A score of ≥3 in any 
category or score ≥5 overall triggers urgent patient review.
Disease-specific tools, such as CURB65, are recom-
mended by respiratory societies worldwide.9 10 20 Each of 
altered mentation, blood urea >7.0, RR ≥30, SBP <90 or 
diastolic BP ≤60 and age ≥65 scores one point, with scores 
≥2 considered moderate–severe. Original validation of 
this tool, however, excluded patients from long-term care 
facilities as well as those with common comorbidities.12
In addition, attempts have been made to refine previ-
ously well-described scores by using biomarkers such 
as lactate. Lactate is a strong independent predictor of 
mortality in both pneumonia and sepsis,13 21 and work 
by other groups has shown that addition of lactate ≥1.8 
mmol/L improves the ability of CURB65 to predict 
mortality.7 13
Existing evidence supports early intervention and 
consideration of ICU for appropriate patients8 12 22 
using severity assessment tools to aid decision-making; 
however, the evidence to support one tool over another 
is lacking in patients with pneumonia. We compared 
the performance of four commonly used severity assess-
ment tools (CURB65, Lac-CURB-65, NEWS and qSOFA) 
in a CAP-specific population to identify those at risk of 
adverse outcomes. We selected these four scores as they 
are commonly used in clinical practice and most widely 
recommended by sepsis and respiratory societies. We 
hypothesise that pneumonia-specific tools will more accu-
rately predict patients at high risk of adverse outcomes.
Methods
study institution and subjects
All adults admitted to the Queen Elizabeth Hospital 
Birmingham, UK with CAP between October 2014 and 
January 2016 were eligible for inclusion.
CAP cases were identified using the hospital coding 
system retrospectively. CAP was defined using British 
Thoracic Society (BTS) guidelines.9 Senior respira-
tory physicians confirmed the diagnosis of CAP using 
admission documents, radiology and electronic patient 
records. Cases were excluded if there were no new infil-
trates in relevant radiological investigations. We identi-
fied patients who would have been previously identified 
as healthcare-associated pneumonia (HCAP). Patients 
with hospital-acquired pneumonia (HAP) were excluded. 
HAP and HCAP were defined using the 2005 Amer-
ican Thoracic Society (ATS) and Infectious Diseases 
Society of America guidelines.10 Ethics was deemed not 
to be required based on the Health Research Authority 
decision tool.23 This was confirmed by our institution’s 
research team and local approval was granted.
In addition to the first set of physiological observations 
recorded on admission to hospital (level of alertness, 
respiratory rate, temperature, oxygen saturations, BP 
and heart rate), the first set of biochemical and haema-
tological laboratory results were also collected from the 
electronic patient record.
CURB65,12 Lac-CURB-65,13 NEWS16 and qSOFA15 
scores were calculated as previously described.
To assess for confusion in qSOFA, CURB65 and 
Lac-CURB-65, we reviewed the admission document 
and scored for confusion if any of the following were 
documented: abnormal AVPU score (alert, response to 
voice, pain or unresponsive), Glasgow coma scale ≤13, 
abnormal mental state examination, or documentation 
of confusion or delirium.
Lac-CURB-65 score and NEWS were grouped into 
predefined ‘Low’, ‘Moderate’ and ‘High’ risk categories. 
Lac-CURB-65 cut-offs: low—CURB-65 ≤1 and/or lactate 
<2.0 mmol/L; moderate—CURB65=2 and/or lactate 
2.0–4.0 mmol/L; high—CURB65 ≥3 and/or lactate >4.0 
mmol/L.13
NEWS cut-offs: low—aggregate score 1–4; medium—
aggregate score 5–6 or a score of ≥3 in a single category; 
high—aggregate score ≥7 as previously defined.16
Outcome measures included admission to ICU, 
length of stay and in-hospital, 30-day, 90-day and 365-day 
mortality; data were collected from the electronic patient 
record.
Patient and public involvement
Patient and the public were not involved in the devel-
opment of this research. This study was undertaken in 
accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines for 
cohort studies.
statistical analysis
Comparison of proportions was performed using the 
χ2 test for trend; trends in median length of stay were 
assessed using the Jonckheere-Terpstra test. Sensitivity, 
specificity, receiver operating characteristic (ROC) curve 
analysis, positive and negative predictive values, and like-
lihood ratios were calculated for each scoring system. 
Cases with missing data were excluded from analysis 
on a score-by-score basis. To assess the effect of missing 
data, analyses were repeated using multiple imputation 
and assumption of normal values where data points 
were absent. These analyses and detailed explanation of 
methods are presented in the online supplement. Statis-
tical analysis was carried out using IBM SPSS Statistics for 
Windows V.24.0 and R (V.3.4.4, Vienna, Austria).
results
Participant demographics
A total of 2895 patients were coded as having CAP and 
1545 were included in the final analysis (figure 1). Due 
to missing data, there were variable numbers of cases 
included in the analysis for each score (figure 1). For a 
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Figure 1 Modified CONSORT diagram demonstrating 
patient inclusion and exclusion pathways. *Reasons 
for exclusion of patients for each severity assessment 
tool (number of cases excluded). Some cases were 
excluded due to more than one missing data point: 
CURB65: Confusion (230), urea (5), respiratory rate (4), 
blood pressure (4), age >65 years (0). Lac-CURB-65: as 
for CURB65 plus lactate (227). qSOFA: mentation (230), 
respiratory rate (4), blood pressure (4). NEWS: temperature 
(9), oxygen saturations (5), level of consciousness (4), 
respiratory rate (4), blood pressure (4), heart rate (4). 
CAP, community-acquired pneumonia; HAP, hospital-
acquired pneumonia; NEWS, National Early Warning Score; 
qSOFA, quick Sequential (Sepsis-related) Organ Failure 
Assessment.
detailed comparison of missing and included cases, see 
the online supplementary eTables 3–7.
The median age of patients included was 76 (IQR 
63–85). Of all cases, 50.8% (785) were men; 29.0% (449) 
of cases fulfilled the criteria for what was previously 
defined as HCAP. Eighty-nine per cent of cases had at 
least one comorbidity (online supplementary eTable 2). 
Overall 30-day mortality was 19.0%; in-hospital mortality 
was 15.4% with an ICU admission rate of 6.4%. Full 
demographic and outcome information is available in 
the online supplement (online supplementary eTable 2).
Validation of curb65 for patients previously defined as hcAP
In 2005, HCAP was defined as a separate entity to CAP in 
order to describe a population of patients in long-term 
care or receiving home-based or hospital-based intrave-
nous therapy or dialysis who had increased mortality24 
and high prevalence of antibiotic-resistant pathogens.25 
The concept of HCAP has more recently been rejected; 
however, the original validation of the CURB65 score 
excluded those that were labelled as HCAP. This has 
led to widespread use of CURB65 in a patient popula-
tion it was not originally validated in. We analysed the 
non-HCAP and HCAP groups separately for CURB65 
to ensure that there was no significant difference in risk 
stratification between the two groups.
CURB65 scoring was possible for 1311 (84.9%) of all 
cases, with complete data available for 83.5% (375) of 
patients with HCAP and 85.4% (936) of patients without 
HCAP (table 1).
CURB65 score was able to stratify according to 
increasing risk of in-hospital mortality as well as 30-day, 
90-day and 365-day mortality (table 1). Increasing 
CURB65 score was not associated with increased likeli-
hood of ICU admission (table 1). Increasing length of 
stay was significantly associated with increased CURB65 
score in the whole cohort as well as the non-HCAP group, 
but not in the HCAP-alone group.
Ability of different severity scoring systems to risk stratify
Increasing NEWS and qSOFA scores were significantly 
associated with increased risk of ICU admission during 
admission (table 2). Increasing severity score was signif-
icantly associated with increased risk of mortality for all 
four scoring systems. Increasing scores were also associ-
ated with increased length of stay for all scoring tools.
overall accuracy of the different scoring systems to predict 
30-day mortality
Overall accuracy of the scoring systems to identify those 
at risk of death within 30 days of presentation to hospital 
was calculated using ROC curve analysis (figure 2). The 
area under the ROC curve (AUROC) for CURB65, 
Lac-CURB-65, NEWS and qSOFA were 0.69, 0.68, 0.63 
and 0.62, respectively. AUROC values were significantly 
greater for CURB65 and Lac-CURB-65 scoring systems 
when compared with those generated using the qSOFA 
criteria (CURB65 vs qSOFA p<0.0001, Lac-CURB-65 vs 
qSOFA p=0.0024) (table 3).
Performance characteristics of severity assessment tools
With 30-day mortality as the outcome measure, we 
calculated the performance characteristics of each of 
the scoring systems using previously defined cut-off 
points.13 15 Lac-CURB-65, using ‘moderate’ as the cut-off, 
had the greatest sensitivity and negative predictive value 
(NPV), 96.4% and 95.6%, respectively. This was closely 
followed by CURB65 with a cut-off of ≥2 giving a sensi-
tivity of 85.0% and NPV of 91.5%. qSOFA had the 
poorest sensitivity at 40.3%, but relatively high specificity 
of 79.9% (table 4).
Assessment of the impact of missing values on the analysis
To assess the impact of missing data, patient characteris-
tics and outcome measure data were compared between 
those with complete data and those without for each 
severity assessment tool (online supplementary eTables 
3–7). The complete analysis was repeated having replaced 
the absent data with either normal values or by using 
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Table 1 CURB65 as a prognostic tool for different outcome measures stratified by CAP aetiology
Outcome 
CURB65 score
P value 0 1 2 3 4 5
n  
  All 173 287 395 309 129 18
  HCAP 27 65 106 113 54 10
  Non-HCAP 146 222 289 196 75 8
30-day mortality n (%)  
  All 6
(3.5)
33
(11.5)
73 (18.5) 83
(26.9)
58
(45.0)
7
(38.9)
<0.001
  HCAP 0
(0.0)
10
(15.4)
25
(23.6)
36
(31.9)
27 (50.0) 3
(30.0)
<0.001
  Non-HCAP 6
(4.1)
23
(10.3)
48
(16.6)
47
(24.0)
31
(41.3)
4
(50.0)
<0.001
90-day mortality n (%)  
  All 10
(5.8)
45
(15.7)
103
(26.1)
108
(35.0)
65
(50.4)
7
(38.9)
<0.001
  HCAP 1
(3.7)
15
(41.5)
28
(39.6)
46
(47.8)
29
(63.0)
3
(30.0)
<0.001
  Non-HCAP 9
(6.2)
30
(13.5)
75
(26.0)
62
(31.6)
36
(48.0)
4
(50.0)
<0.001
365-day mortality n (%)  
  All 11
(6.4)
69
(24.0)
132
(33.4)
143
(46.3)
73
(56.6)
7
(38.9)
<0.001
  HCAP 1
(3.7)
27
(41.5)
42
(39.6)
54
(47.8)
34
(63.0)
3
(30.0)
<0.001
  Non-HCAP 10
(6.9)
42
(18.9)
90
(31.1)
89
(45.4)
39
(52.0)
4
(50.0)
<0.001
In-hospital death n (%)  
  All 3
(1.7)
25
(8.7)
60
(15.2)
67
(21.7)
48
(37.2)
5
(27.8)
<0.001
  HCAP 0
(0.0)
8
(12.3)
17
(16.0)
25
(22.1)
19
(35.2)
1
(10.0)
<0.001
  Non-HCAP 3
(2.1)
17
(7.7)
43
(14.9)
42
(21.4)
29
(38.7)
4
(50.0)
<0.001
ICU admission n (%)  
  All 12
(6.9)
15
(5.2)
39
(9.9)
13
(4.2)
6
(4.7)
2
(11.1)
0.514
  HCAP 2
(7.4)
3
(4.6)
4
(3.8)
2
(1.8)
1
(1.9)
1
(10.0)
0.285
  Non-HCAP 10
(6.8)
12
(5.4)
35
(12.1)
11
(5.6)
5
(6.7)
1
(12.5)
0.733
Length of inpatient stay 
median days (IQR)
 
  All 3
(1.0–7.0)
6
(3.0–13.0)
8
(4.0–15.0)
9
(5.0–17.0)
8
(4.0–13.5)
8.5
(4.5–14.0)
<0.001
  HCAP 5
(2.0–10.0)
9
(4.0–17.5)
9
(5.0–16.3)
8
(4.5–15.5)
8
(5.0–12.0)
7.5
(4.5–17.3)
0.529
  Non-HCAP 3
(1.0–7.0)
6
(3.0–11.0)
8
(4.0–14.5)
9.5
(5.0–20.8)
7
(4.0–16.0)
9
(3.8–12.3)
<0.001
Comparison of proportions performed using χ2 test for trend. Trends in median length of stay assessed using the Jonckheere-Terpstra test.
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit.
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Table 2 Ability of severity assessment tools to risk stratify for outcome measures in CAP
Outcome 
CURB65
P value 
0
n=173
1
n=287
2
n=395
3
n=309
4 
 n=129
5
n=18
30-day mortality n (%) 6
(3.5)
33
(11.5)
73
18.5)
83
(26.9)
58
(45.0)
7
(38.9)
<0.001
90-day mortality n (%) 10
(5.8)
45
(15.7)
103
(26.1)
108
(35.0)
65
(50.4)
7
(38.9)
<0.001
365-day mortality n (%) 11
(6.4)
69
(24.0)
132
(33.4)
143
(46.3)
73
(56.6)
7
(38.9)
<0.001
In-hospital death n (%) 3
(1.7)
25
(8.7)
60
(15.2)
67
(21.7)
48
(37.2)
5
(27.8)
<0.001
ICU admission n (%) 12
(6.9)
15
(5.2)
39
(9.9)
13
(4.2)
6
(4.7)
2
(11.1)
0.514
Length of inpatient stay 
median days (IQR)
3
(1.0–7.0)
6
(3.0–13.0)
8
(4.0–15.0)
9
(5.0–17.0)
8
(4.5–13.5)
9
(4.5–
14.0)
<0.001
Lac-CURB-65
 Low 
n=204
Moderate 
n=506
High 
n=503
30-day mortality n (%) 9
(4.4)
77
(15.2)
166
(33.0)
<0.001
90-day mortality n (%) 15
(7.4)
107
(26.8)
199
(39.6)
<0.001
365-day mortality n (%) 29
(14.2)
143
(28.3)
243
(48.3)
<0.001
In-hospital death n (%) 5
(2.5)
62
(12.3)
134
(26.6)
<0.001
ICU admission n (%) 10
(4.9)
41
(8.1)
36
(7.1)
0.483
Length of inpatient stay 
median days (IQR)
6
(2.0–10.0)
7
(4.0–13.0)
8
(5.0–16.0)
<0.001
NEWS
 Low 
n=557
Moderate 
n=417
High 
n=560
30-day mortality n (%) 61
(11.0)
61
(14.6)
168
(30.0)
<0.001
90-day mortality n (%) 96
(17.2)
93
(22.3)
197
(35.2)
<0.001
365-day mortality n (%) 137
(24.6)
125
(30.0)
243
(43.4)
<0.001
In-hospital death n (%) 56
(10.1)
52
(12.5)
127
(22.7)
<0.001
ICU admission n (%) 12
(2.1)
25
(6.0)
58
(10.4)
<0.001
Length of inpatient stay 
median days (IQR)
6
(3.0–12.0)
7
(4.0–16.0)
8
(4.0–14.8)
<0.001
qSOFA score
 0
n=369
1
n=629
2
n=265
3
n=52
30-day mortality n (%) 43
(11.7)
114
(18.4)
82
(30.9)
24
(46.2)
<0.001
Continued
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Outcome 
CURB65
P value 
0
n=173
1
n=287
2
n=395
3
n=309
4 
 n=129
5
n=18
90-day mortality n (%) 62
(16.8)
154
(24.5)
100
(37.7)
25
(48.1)
<0.001
365-day mortality n (%) 86
(23.3)
205
(32.6)
119
(44.9)
28
(53.8)
<0.001
In-hospital death n (%) 36
(9.8)
86
(13.7)
68
(25.7)
20
(38.5)
<0.001
ICU admission n (%) 13
(3.5)
49
(7.8)
22
(8.3)
3
(5.8)
0.038
Length of inpatient stay 
median days (IQR)
6
(3.0–11.0)
7
(4.0–15.0)
8
(4.0–15.0)
8
(5.0–15.75)
<0.001
Comparison of proportions done using χ2 test for trend. Trends in median length of stay assessed using the Jonckheere-Terpstra test.
Lac-CURB-65 cut-offs: low—CURB-65 ≤1 and/or lactate <2.0 mmol/L; moderate—CURB65=2 and/or lactate 2.0–4.0 mmol/L; high—
CURB65 ≥3 and/or lactate >4.0 mmol/L. NEWS score cut-offs: low—aggregate score 1–4; medium—aggregate score 5–6 or a score of ≥3 in 
a single category; high—aggregate score ≥7 as previously defined.13 16
CAP, community-acquired pneumonia; ICU, intensive care unit; NEWS, National Early Warning Score; qSOFA, quick Sequential (Sepsis-
related) Organ Failure Assessment.
Table 2 Continued
Figure 2 Receiver operating characteristic (ROC) curves 
to assess overall accuracy of severity assessment tools 
using 30-day mortality as the standard. Area under the 
ROC curve for CURB65, Lac-CURB-65, NEWS and qSOFA 
were 0.69, 0.68, 0.63 and 0.62, respectively. NEWS, 
National Early Warning Score; qSOFA, quick Sequential 
(Sepsis-related) Organ Failure Assessment.
Table 3 Comparison of overall accuracy of severity 
assessment tools to predict 30-day mortality at admission
(P value) CURB65 Lac-CURB-65 NEWS qSOFA
CURB65
Lac-CURB-65 0.4827
NEWS 0.0054 0.0138
qSOFA <0.001 0.0024 0.7858
Receiver operating curve analysis was performed and the table 
presents the p values following comparison of the area under 
the curve for each assessment tool using 30-day mortality as the 
standard. Comparison was performed using DeLong’s test.
NEWS, National Early Warning Score; qSOFA, quick Sequential 
(Sepsis-related) Organ Failure Assessment.
multiple imputation. The full results of these analyses 
can be reviewed in the online supplement (see online 
supplementary eTables 8–14). Both the assumed normal 
and multiple imputation analyses resulted in little signifi-
cant change in the results.
dIscussIon
This study describes a large cohort of hospitalised CAP 
and confirms that CURB65, Lac-CURB-65, NEWS and 
qSOFA scores at the time of hospital admission can stratify 
according to increasing risk of mortality in all patients 
with CAP. These data also suggest that using a ‘moderate’ 
Lac-CURB-65 score as a threshold for identifying those 
at increased risk of 30-day mortality may have utility as a 
‘rule-out’ when assessing patients that may need escala-
tion of care.
A key strength of this study was the use of a pragmatic 
approach to patient inclusion, which has led to the valida-
tion of these assessment tools in patients often excluded 
from other studies but among which the severity assess-
ment scores are commonly used. Patients excluded from 
the original validation of the CURB65 score included 
those with bronchiectasis, malignancy, prior hospital 
admission within 14 days, immunocompromise, nursing 
home residents or where pneumonia was an expected 
terminal event.12 The generalisability of our findings 
to real-life patient populations has been increased by 
including these patients.
A previous study has demonstrated that CURB65 had 
greater predictive ability for adverse outcomes in CAP 
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Table 4 Performance characteristics of the severity scoring systems using 30-day mortality as the outcome measure
Score
(n)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%) NLR PLR
CURB65 ≥2
(851)
85.0 40.1 26.0 91.5 0.37 1.42
CURB65 ≥3
(456)
56.9 70.1 32.5 86.9 0.61 1.94
Lac-CURB-65 ≥moderate
(1009)
96.4 20.3 24.1 95.6 0.18 1.21
Lac-CURB-65
high
(503)
65.9 64.9 33 87.9 0.53 1.88
qSOFA*
(317)
40.3 79.9 33.4 84.3 0.75 2.01
NEWS ≥medium
(997)
79 39.9 23.4 89.1 0.53 1.31
NEWS high
(560)
57.9 68.5 30.0 87.5 0.61 1.84
*Cut-off value for qSOFA was ≥2.
NEWS, National Early Warning Score; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio;PPV, 
positive predictive value;qSOFA, quick Sequential (Sepsis-related) Organ Failure Assessment.
than systemic inflammatory response syndrome criteria 
or early warning scores26; however, we have used addi-
tional, comparatively novel scoring systems and applied 
them to a larger cohort of patients with more pragmatic 
inclusion criteria and measured long-term mortality 
outcomes.26
The diagnosis of pneumonia has been verified by the 
review of radiological and clinical findings. A key finding 
of the UK-wide BTS pneumonia audit was that using clin-
ical coding alone led to misdiagnosis in approximately a 
third of cases due to lack of clinicoradiographic features 
of pneumonia,27 a finding borne out by this study.
Increasing NEWS and qSOFA scores were associated 
with increased rate of admission to ICU. It should be 
noted that during the study period, all scores were being 
used in clinical practice, except for qSOFA, and this 
may have had an impact on the decision-making process 
when a patient was admitted to ICU. Our ICU admission 
rate is lower than that seen in studies performed outside 
the UK7 15 28; however, it is in keeping with the BTS pneu-
monia audit.27 This is likely to be due to inclusion of 
patients with treatment limitations; we choose to include 
patients with treatment limitations to enable applica-
tion of these scores to all patients admitted. Prediction 
of adverse outcome remains important for all patients, 
even if they would be unlikely to benefit from ICU admis-
sion as it informs decision-making regarding appro-
priate interventions that can be implemented, as well as 
informing decisions regarding withdrawal of care in cases 
where further treatment may be futile.
The qSOFA tool was designed as a quick and easy 
screening tool, to allow repeated and widespread use 
to identify deteriorating patients.15 It was interesting to 
note that the sensitivity of the qSOFA score to predict 
30-day mortality, when performed at the time of admis-
sion, was low in this CAP population, an observation that 
has been made in previous studies.28 29 qSOFA was more 
accurate at predicting ICU admission in this study and 
previous work.30 This suggests that though serial scoring 
may have use in identifying those that are deteriorating, 
in this cohort of patients with CAP, there was little use of 
the score as an indicator of 30-day mortality at the time 
of admission. The validation study for qSOFA defined 
adverse outcome as in-hospital mortality or ICU admis-
sion for greater than 3 days15; our different definition of 
adverse outcome may also affect interpretation of these 
data.
A raised lactate has been consistently demonstrated 
to be an independent predictor of mortality in sepsis21 
and pneumonia.7 Frenzen et al found that addition of 
lactate ≥1.8 mmol/L significantly improved the ability of 
CURB65 to predict a combined endpoint of ICU admis-
sion and inpatient mortality,7 similarly confirmed by 
Chen and Li.13 However, this effect was not observed in 
our cohort for ICU admission or 30-day mortality. This 
is likely to be due to key differences in study design and 
populations. For example, Frenzen et al excluded any 
patients with treatment limitations and had a high ICU 
admission rate (22%) with very low mortality (7%). Our 
mortality rates were in keeping with those from the BTS 
pneumonia audit27 and large European cohorts.2 Thir-
ty-day mortality was higher than in-hospital mortality, and 
this is likely to reflect the increased long-term mortality31 
and high rates of re-admission seen after CAP27; this is 
especially true for older people as seen in this study.
Increasing age is well recognised to be an independent 
risk factor for mortality in CAP32 and is represented in 
CURB65. Greater than two-thirds of participants in this 
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cohort were ≥65 years of age, meaning they score highly 
when using CURB65, whereas NEWS and qSOFA do 
not account for age. In the future, it would be pertinent 
to assess for impact of age on scoring systems to see if 
dichotomising by age criteria improves predictive ability.
To compare the overall accuracy of the scores to 
predict 30-day mortality, ROC curves were calculated. 
Though CURB65 and Lac-CURB-65 resulted in a signifi-
cantly greater AUROC compared with qSOFA, the clin-
ical significance of this difference is difficult to define, 
and none of the scores provided excellent discrimination 
of patients at high risk of adverse outcomes. The use 
of different inclusion criteria and management strate-
gies, combined with different outcome measures used 
in previous studies, makes direct comparison with our 
findings challenging. The AUROC for the CURB65 has 
been reported as ranging from 0.717 to 0.8298 28 33 in 
CAP populations (with patients with HCAP excluded), to 
0.6534 in a cohort which included patients with HCAP, 
similar to findings presented here. The use of CURB65 
in the HCAP population has been validated previously by 
Ewig et al.35
Goulden et al18 used NEWS and qSOFA to predict 
mortality in a group of emergency admissions with sepsis 
and also found similar AUROCs to those presented here 
(0.65 and 0.62, respectively). A meta-analysis of qSOFA 
in predicting mortality identified an AUROC of 0.67; 
however, the sensitivity of qSOFA was very low.29 Brabrand 
and Henriksen found that CURB65 was not superior 
to NEWS in predicting 30-day mortality.36 A large CAP 
cohort study using the CAPNETZ37 database found that 
qSOFA plus age ≥65 years was as good at predicting 30-day 
mortality as CRB65.38 Data presented here for patients 
with CAP support other data in the literature and may 
suggest that the qSOFA score may not perform as well in 
a CAP-specific population when compared with a mixed 
sepsis population. The low AUROCs seen for these scores 
and by other groups demonstrate the weaknesses of these 
severity scoring systems in common clinical practice and 
highlight the need for better tools.
This study has limitations, including the retrospec-
tive single-centre study design and missing data. The 
most common missing data was documentation of 
the patient’s mental state. This may have introduced 
bias when comparing the different scoring systems. 
To account for this, we have presented analyses using 
multiple imputation and assumption of normal values. 
It is reassuring to note that there were no significant 
changes in the results when these alternative analysis 
methods were employed. With regards to prediction of 
ICU admission, we did not exclude patients with treat-
ment limitations and this may have impacted on accu-
racy of these scores to predict ICU admission. Prospective 
multicentre studies to ensure collection of complete data 
sets and ensure generalisability are needed. In addition, 
further studies are warranted to examine the role of 
serial scoring to predict deterioration during an admis-
sion, rather than assessing risk at the time of admission. 
NEWS and qSOFA have already demonstrated validity for 
serial scoring16 17; however, this has not been assessed for 
the pneumonia-specific scores.
We recognise that other severity scoring tools exist for 
pneumonia and are more widely used outside the UK39; 
however, we opted for commonly used and simple scores 
that could be calculated at the point of admission rather 
than complex tools such as pneumonia severity index.
None of the commonly used existing tools provide 
excellent discrimination of patients at high risk of adverse 
outcomes, and more sophisticated scoring systems exist 
such as SOFA for sepsis or ATS minor criteria which 
provide better discrimination. However, refinement of 
existing simple tools or investigation of novel markers 
for poor prognosis in CAP would be beneficial. Further-
more, these data do not assist with the risk stratification 
of patients with HAP, and further studies are needed in 
this patient population. The development of an accurate 
risk stratification tool for CAP and HAP could lead to 
earlier identification of patients who would benefit from 
early escalation and targeted treatment.12 22
conclusIon
These data suggest that four commonly used severity 
assessment tools are able to stratify patients according 
to increasing risk of mortality. Furthermore, a ‘low’ 
Lac-CURB-65 score appears to indicate that a poor 
outcome is unlikely. Tools specifically designed for sepsis 
and early recognition of patients at increased risk of ICU 
admission did not perform as well as the CAP-specific 
tools, particularly when compared with previous studies 
of all-cause sepsis, suggesting that organ-specific severity 
assessment tools may have greater use in early recogni-
tion of patients who are at risk of adverse outcomes.
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